Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) (original) (raw)

• Fiers, W. Biologic therapy with TNF: preclinical studies In Biologic therapy of cancer: principles and practice. (eds DeVita, V., Hellman, S. & Rosenberg, S.) 295–327 (J.B. Lippincott, Philadelphia; 1995).
  Google Scholar
• Carswell, E.A. et al. An endotoxin-induced serum factor that causes necrosis of tumors . Proc. Natl. Acad. Sci. USA 72, 3666– 3670 (1975).
  Article CAS Google Scholar
• Fraker, D.L., Alexander, H.R. & Pass, H.I. Biologic therapy with TNF: systemic administration and isolation perfusion. In Biologic therapy of cancer: principles and practice. (eds DeVita V., Hellman, S. & Rosenberg, S.) 329–345 (J.B. Lippincott, Philadelphia; 1995).
  Google Scholar
• Lienard, D., Ewalenko, P., Delmotte, J.J., Renard, N. & Lejeune, F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52–60 (1992).
  Article CAS Google Scholar
• Eggermont, A.M. et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 14, 2653–2665 (1996).
  Article CAS Google Scholar
• Fraker, D.L., Alexander, H.R., Andrich, M. & Rosenberg, S.A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 14, 479–489 ( 1996).
  Article CAS Google Scholar
• Alexander, H.R. Jr. et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16, 1479–1489 (1998).
  Article CAS Google Scholar
• Corti, A. & Marcucci, F. Tumour necrosis factor: strategies for improving the therapeutic index. J. Drug Targ. 5, 403–413 (1998).
  Article CAS Google Scholar
• Gasparri, A. et al. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res. 59, 2917–2923 ( 1999).
  CAS PubMed Google Scholar
• Nawroth, P. et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168, 637–647 (1988).
  Article CAS Google Scholar
• Nawroth, P.P. & Stern, D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163, 740–745 ( 1986).
  Article CAS Google Scholar
• Palladino, M.A. Jr. et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 138 , 4023–4032 (1987).
  CAS PubMed Google Scholar
• Clauss, M. et al. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin . J. Biol. Chem. 265, 7078– 7083 (1990).
  CAS PubMed Google Scholar
• Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380 (1998).
  Article CAS Google Scholar
• Pasqualini, R., Koivunen, E. & Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542–546 (1997).
  Article CAS Google Scholar
• Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768–774 (1999).
  Article CAS Google Scholar
• Pasqualini, R. et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722–727 (2000).
  CAS PubMed PubMed Central Google Scholar
• Smith, R.A. & Baglioni, C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem. 262 , 6951–6954 (1987).
  CAS PubMed Google Scholar
• Moro, M. et al. Tumor cell targeting with antibody–avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res. 57, 1922–1928 (1997).
  CAS PubMed Google Scholar
• Stryhn Hansen, A., Noren, O., Sjostrom, H. & Werdelin, O. A mouse aminopeptidase N is a marker for antigen-presenting cells and appears to be co-expressed with major histocompatibility complex class II molecules . Eur. J. Immunol. 23, 2358– 2364 (1993).
  Article Google Scholar
• Taylor, A. Aminopeptidases: structure and function. FASEB J. 7 , 290–298 (1993).
  Article CAS Google Scholar
• Shipp, M.A. & Look, A.T. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key. Blood 82, 1052–1070 ( 1993).
  CAS PubMed Google Scholar
• Talmadge, J.E., Tribble, H.R., Pennington, R.W., Phillips, H. & Wiltrout, R.H. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res. 47, 2563–2570 (1987).
  CAS PubMed Google Scholar
• Pfizenmaier, K., Scheurich, P., Schluter, C. & Kronke, M. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J. Immunol. 138, 975– 980 (1987).
  CAS PubMed Google Scholar
• Asher, A.L. et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors . J. Immunol. 146, 3227– 3234 (1991).
  CAS PubMed PubMed Central Google Scholar
• Schraffordt Koops, H. et al. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Radiother. Oncol. 48, 1–4 (1998).
  Article CAS Google Scholar
• Lienard, D., Lejeune, F.J. & Ewalenko, P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J. Surg. 16, 234–240 (1992).
  Article CAS Google Scholar
• Hill, S. et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br. J. Surg. 80, 995– 997 (1993).
  Article CAS Google Scholar
• Eggermont, A.M. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 224, 756–765 ( 1996).
  Article CAS Google Scholar
• Corti, A. et al. Tumor targeting with biotinylated tumor necrosis factor alpha: structure–activity relationships and mechanism of action on avidin pretargeted tumor cells. Cancer Res. 58, 3866–3872 (1998).
  CAS PubMed Google Scholar
• Ljunggren, H.G. & Karre, K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162, 1745– 1759 (1985).
  Article CAS Google Scholar
• Celik, C., Lewis, D.A. & Goldrosen, M.H. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res. 43, 3507– 3510 (1983).
  CAS PubMed Google Scholar
• Pennica, D., Hayflick, J.S., Bringman, T.S., Palladino, M.A. & Goeddel, D.V. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc. Natl. Acad. Sci. USA 82, 6060 –6064 (1985).
  Article CAS Google Scholar
• Corti, A., Poiesi, C., Merli, S. & Cassani, G. Tumor necrosis factor (TNF) alpha quantification by ELISA and bioassay: effects of TNF alpha-soluble TNF receptor (p55) complex dissociation during assay incubations. J. Immunol. Methods 177, 191–198 (1994).
  Article CAS Google Scholar
• Gasparri, A. et al. Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. J. Biol. Chem. 272, 20835–20843 (1997).
  Article CAS Google Scholar